• Using quantitative imaging of fluorescent biosensors of action potential-evoked synaptic vesicle exocytosis (synaptophysin-pHluorin) and Ca 2+ influx (GCaMP6) in cultured rat hippocampal neurons, it was found that synaptic vesicle exocytosis was inhibited by both dexmedetomidine and clonidine in proportion to reduced Ca 2+ entry • These effects were specifically due to activation of α 2Aadrenoceptors and were additive with inhibition of release by isoflurane ABSTRACT Background: evidence indicates that the anesthetic-sparing effects of α 2 -adrenergic receptor (ar) agonists involve α 2a -ar heteroreceptors on nonadrenergic neurons. Since volatile anesthetics inhibit neurotransmitter release by reducing synaptic vesicle (SV) exocytosis, the authors hypothesized that α 2 -ar agonists inhibit nonadrenergic SV exocytosis and thereby potentiate presynaptic inhibition of exocytosis by isoflurane. Methods: Quantitative imaging of fluorescent biosensors of action potential-evoked SV exocytosis (synaptophysin-pHluorin) and Ca 2+ influx (GCaMP6) were used to characterize presynaptic actions of the clinically used α 2 -ar agonists dexmedetomidine and clonidine, and their interaction with isoflurane, in cultured rat hippocampal neurons. Results: Dexmedetomidine (0.1 μM, n = 10) or clonidine (0.5 μM, n = 8) inhibited action potential-evoked exocytosis (54 ± 5% and 59 ± 8% of control, respectively; P < 0.001). effects on exocytosis were blocked by the subtype-nonselective α 2 -ar antagonist atipamezole or the α 2a -ar-selective antagonist Brl 44408 but not by the α 2C -ar-selective antagonist JP 1302. Dexmedetomidine inhibited exocytosis and presynaptic Ca 2+ influx without affecting Ca 2+ coupling to exocytosis, consistent with an effect upstream of Ca 2+ -exocytosis coupling. exocytosis coupled to both n-type and P/Q-type Ca 2+ channels was inhibited by dexmedetomidine or clonidine. Dexmedetomidine potentiated inhibition of exocytosis by 0.7 mM isoflurane (to 42 ± 5%, compared to 63 ± 8% for isoflurane alone; P < 0.05).
G eneral anesthesia is a reversible drug-induced state of neurologic unresponsiveness characterized by amnesia, unconsciousness, and immobility in response to painful stimuli. The molecular and cellular mechanisms that produce these key pharmacologic features are poorly understood. 1 all general anesthetics modulate synaptic transmission and neuronal excitability, altering the balance between excitation and inhibition and reducing connectivity in central nervous system networks. 2, 3 The principal molecular targets underlying these cellular and network effects include both ligand-gated and voltage-gated ion channels. 1, 4 Dexmedetomidine and clonidine are not general anesthetics themselves but produce sedative-hypnotic and anestheticsparing effects through activation of G protein-coupled α 2a -adrenergic receptors (α 2a -ars). 5, 6 The downstream targets coupled to α 2a -ar activation that contribute to their anesthetic-sparing effects are incompletely characterized. a well-described effect of α 2 -ar agonists is suppression of norepinephrine release from noradrenergic locus coeruleus (lC) neurons through inhibitory autoreceptor activation. 7 This mechanism was originally suggested to underlie the sedative action of dexmedetomidine. 8 However, genetic analysis of the functional roles of α 2 -ar subtypes in adrenergic and nonadrenergic cells indicates that the sedative-hypnotic effects of α 2 -ar agonists are mediated not by presynaptic α 2a -ar autoreceptors but rather by α 2a -ar heteroreceptors on nonadrenergic neurons. 9 Moreover, the cellular locations and actions of these critical nonadrenergic neuronal α 2a -ars responsible for the sedative and anesthetic-sparing actions of α 2 -ar agonists are unknown. 10 Volatile anesthetics are known to inhibit the release of multiple neurotransmitters through direct presynaptic What We Already Know about This Topic • Volatile anesthetics inhibit neurotransmitter release by reducing synaptic vesicle exocytosis • The authors tested the hypothesis that α 2 -adrenoceptor agonists potentiate presynaptic inhibition of nonadrenergic synaptic vesicle exocytosis by isoflurane mechanisms, including more potent inhibition of the release of glutamate, the principal excitatory neurotransmitter in the central nervous system, compared to other neurotransmitters. [11] [12] [13] [14] Since α 2 -ar agonists reduce requirements for general anesthetics, 15 we hypothesized that they also affect nonadrenergic synaptic transmission through presynaptic effects on evoked neurotransmitter release. reduced excitatory transmission resulting in alteration of the balance between neuronal excitation and inhibition has been implicated in the effects of volatile anesthetics 1, 16 and provides a plausible mechanism for the well-known pharmacologic interaction underlying the anesthetic-sparing effects of α 2ar agonists. α 2a -ars are expressed widely in neurons throughout the central nervous system, 17, 18 primarily at presynaptic rather than postsynaptic sites, 9, 19 consistent with a role for presynaptic α 2a -ars on nonadrenergic neurons in their neuropharmacologic effects. Suppression of both excitatory and inhibitory neurotransmission by α 2 -ar agonists has been shown by electrophysiologic recordings in brain slices, 20,21 but since neurotransmitter release was not measured directly, these synaptic effects could be mediated postsynaptically or indirectly through intrinsic noradrenergic afferents rather than by direct presynaptic actions on heterosynaptic α 2a -ars. We, therefore, studied the effects and α 2 -ar receptor subtype specificity of the clinically used α 2 -ar agonists dexmedetomidine and clonidine and their pharmacodynamic interaction with isoflurane on action potential (aP)-evoked synaptic vesicle (SV) exocytosis and presynaptic Ca 2+ influx in cultured rat hippocampal neurons using quantitative biosensor fluorescence live-cell imaging approaches. [22] [23] [24] 
Materials and Methods

Reagents and Solutions
Dexmedetomidine, clonidine, atipamezole, Brl 44408, and JP 1302 were purchased from Tocris Bioscience (United Kingdom); ω-conotoxin GIVa and ω-agatoxin IVa from alomone labs (Israel); bafilomycin a1 from Calbiochem (USa); and isoflurane from abbott (USa). all other reagents were purchased from Sigma-aldrich (USa). The synaptophysin-pHluorin (syn-pH) construct was kindly provided by Yongling Zhu (northwestern University, USa), and the GCaMP6 construct was kindly provided by loren l. looger (Janelia Farm research Campus, Howard Hughes Medical Institute, ashburn, Virginia). 24 Isoflurane-saturated stock solutions (approximately 12 mM) were prepared and diluted daily into gastight glass syringes, from which a sample was taken for determination of aqueous isoflurane concentration. Solutions were perfused focally onto imaged cells via a 150-μm-diameter perfusion pipette using polytetrafluoroethylene tubing to minimize isoflurane loss. Concentrations used corresponded to 1 to 3 times the minimum alveolar concentration in rats corrected to 30°C (0.35 mM). 25 Perfusate samples were taken at the tip of the perfusion manifold to determine delivered isoflurane concentrations and reflected approximately 10% loss from the syringe to the pipette tip. Isoflurane concentrations were determined by extraction into n-heptane (1:1 v/v) followed by analysis using a Shimadzu GC-2010 Plus gas chromatograph (Japan) with external standard calibration. 26 Hippocampal Neuron Culture and Transfection experiments were approved by the Weill Cornell Medical College Institutional animal Care and Use Committee and conformed to national Institutes of Health Guidelines for the Care and Use of animals. Hippocampal Ca3-Ca1 regions were dissected from neonatal Sprague-Dawley rats (1 to 3 days old, male and female), and cells were dissociated and plated as described. 22 neurons were transfected on days 7 to 8 in vitro with the syn-pH or GCaMP6 construct using the Ca 2 PO 4 method, and imaging experiments were conducted on days 14 to 21 in vitro. 23 randomization was not used to assign experimental conditions as the pharmacologic approaches used required specific sequential applications of drugs; therefore, the experimenter was not blinded to the conditions. rat pups born from at least three different parents were used for each set of experiments.
Synaptic Vesicle Exocytosis
Synaptophysin-pHluorin (syn-pH), a fusion protein of the engineered, pH-sensitive green fluorescent protein pHluorin fused to the lumenal n-terminal tail of the synaptic vesicular protein synaptophysin, was used as an optical biosensor of SV exocytosis. 22, 27 Changes in fluorescence (ΔF) during electrical stimulation of aP firing reflect alkalization of pHluorin due to exocytosis, while changes during the poststimulus period reflect reacidification after endocytosis. 22 The transfection method yielded only several transfected cells per dish due to the low transfection efficiency such that boutons from single cells could be identified and imaged without interference from other neurons. live-cell imaging was performed at 30.0° ± 0.2°C with continuous superperfusion at 0.27 ml min −1 with Tyrode solution containing (in mM) 119 naCl, 2.5 KCl, 2 CaCl 2 , 2 MgCl 2 , 25 HePeS buffered to pH 7.4, and 30 glucose, with 10 μM 6-cyano-7-nitroquinoxaline-2,3-dione (CnQX) and 50 μM D,l-2-amino-5-phosphonovaleric acid (aP5) included to block excitatory synaptic transmission and recurrent excitation. Fluorescence images were acquired with an andor iXon1 camera (model DU-897e-BV; United Kingdom) with a solid-state, diode-pumped 488-nm laser shuttered using acousto-optic modulation. Data were acquired at 10 or 100 Hz by integrating for 30 or 9.74 ms in frame transfer mode and restricting imaging to a subarea of the chargecoupled device chip. The ΔF for exocytosis in response to aP trains was defined as the difference between the average of 2 to 10 frames before and after the stimulus.
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aPs were evoked by stimulation with 1-ms current pulses yielding fields of approximately 10 V cm −1 using platinum-iridium electrodes. Cells were allowed to rest approximately 60 s between 20 Hz aP trains and at least 5 min between 10 Hz aP trains. experiments were followed by a maximally depleting stimulus (1,200 aPs at 10 Hz) in the presence of the v-aTPase inhibitor bafilomycin a1 (0.5 μM), which prevents SV reacidification after exocytosis, to determine total recycling pool (TrP) size and then by perfusion with 50 mM nH 4 Cl (substituted for 50 mM naCl and buffered to pH 7.4) to define the total pool (TP) by alkalization of all vesicles. Fluorescence measurements are expressed as a fraction of the TP ( fig. 1 ). 23 
Calcium Measurements
GCaMP6 was used to measure intracellular Ca 2+ ([Ca 2+ ] i ) in hippocampal neuron boutons stimulated by field potentialgenerated aPs in the presence of 2 mM extracellular Ca 2+ ([Ca 2+ ] e ). 24 GCaMP6 peak fluorescence (ΔF) for each stimulus was determined by averaging the two highest points after 
Image and Statistical Analysis
Boutons were selected for analysis by demonstrating their responsiveness to test applications of nH 4 Cl. Peak amplitude at 100 aPs was selected at 10 s in the middle of a 10-Hz 20-s stimulation. Bafilomycin a1 and nH 4 Cl effects were analyzed as mean plateau values. Images were analyzed in ImageJ (national Institutes of Health, USa; http://rsb.info. nih.gov/ij) with a custom plugin (http://rsb.info.nih.gov/ij/ plugins/time-series.html). Silent boutons, defined as those where the response to 100 aPs was smaller than the SD of the baseline before stimulation (ΔF 100 = σ ≤ 0), were excluded from analysis; less than 10% of boutons did not respond to stimulation and were excluded from analysis. Based on previous studies, 13, 14, 22, 23 sample sizes greater than or equal to 5 were used. Data are shown as mean ± SeM. anOVa with Tukey or Bonferroni post hoc tests, two-tailed Student's t test (P < 0.05), and 95% CIs were used for testing statistical significance. GraphPad Prism 6 (GraphPad Software, Inc., USa) was used for statistical analysis. fig. 1D . Fluorescence reached a peak that decayed after the stimulus period due to endocytosis and SV reacidification ( fig. 1D ).
aP-evoked exocytosis was inhibited by the clinically used sedative α 2 -ar agonists dexmedetomidine (0.1 μM; fig. 1 , B, D, and e) or clonidine (0.5 μM; fig. 1 , F and G); these concentrations are known to be effective in vitro. 21, 28 The more selective α 2 -ar agonist dexmedetomidine applied for 15 min reduced peak exocytosis elicited by 100 aPs to 54 ± 5% of control (95% CI, 0.42 to 0.65; fig. 1e ), with no significant difference in effect between 2 and 15 min of dexmedetomidine application, indicating a rapid onset of inhibition. The less selective partial α 2 -ar agonist clonidine inhibited peak SV exocytosis to 59 ± 8% of control (95% CI, 0.40 to 0.78; fig. 1G ). The degree of inhibition of SV exocytosis was less at the end of 60 s of stimulation (600 aP) compared to 10 s of stimulation (100 aP) for dexmedetomidine (95% CI, −0.21 to −0.01; P = 0.04 by two-tailed paired t test, n = 10) or clonidine (95% CI, −0.36 to −0.05; P = 0.016 by two-tailed paired t test, n = 8), indicating that inhibition can be partially overcome by a longer stimulation period ( fig. 1 , e and G). During prolonged stimulation in the presence of bafilomycin a1, neither dexmedetomidine (0.59 ± 0.03; 95% CI, 0.51 to 0.67; P = 0.95; n = 10) nor clonidine (0.61 ± 0.03; 95% CI, 0.54 to 0.68; P = 0.76; n = 8) affected TrP size as a fraction of TP compared to control (0.60 ± 0.03; 95% CI, 0.53 to 0.66; n = 11, by twotailed unpaired t test; data not shown).
Inhibition of Exocytosis Is Mediated by the α 2A -AR Subtype
There are three major α 2 -ar receptor subtypes: α 2a , α 2B , and α 2C. 29 The specific subtype mediating inhibition of SV exocytosis by dexmedetomidine and clonidine was examined using subtype-selective antagonists. Dexmedetomidine (0.1 µM) reduced peak exocytosis elicited by 100 aP to 57 ± 6% of control (95% CI, 0.43 to 0.71; n = 9; fig. 2a ). The nonselective α 2 -ar antagonist atipamezole abolished inhibition of SV exocytosis by dexmedetomidine, indicating a specific α 2 -ar receptor-mediated mechanism (n = 7; fig. 2B ). Treatment with the α 2a -ar-selective antagonist Brl 44408 (1 μM) also blocked inhibition by dexmedetomidine (n = 8; fig. 2C ), while the α 2C -ar-selective antagonist JP 1302 (3 μM) had no effect on inhibition of exocytosis by dexmedetomidine (n = 7; fig. 2D ). Similar receptor subtype selectivity was observed for clonidine (data not shown). These findings indicate that dexmedetomidine and clonidine inhibit SV exocytosis exclusively through interaction with α 2a -ars.
The effects of dexmedetomidine and clonidine on exocytosis evoked by increasing numbers of aPs were also investigated ( fig. 3a) . Peak exocytosis increased incrementally from 1 to 20 aP stimuli. The degree of inhibition by dexmedetomidine was comparable across this range of stimuli (57 to 60% of control; n = 7; fig. 3B ), with inhibition to 60 ± 6% of control at 20 aPs (95% CI, 0.35 to 0.80). Similar results were observed for 0.5 μM clonidine (58 to 65% of control; n = 9; data not shown).
α 2 -AR Agonists Inhibit Exocytosis by Reducing Ca 2+ Influx
Increases in [Ca 2+ ] i were measured in hippocampal boutons using the optogenetic fluorescent reporter GCaMP6 as an indicator of presynaptic Ca 2+ influx. 24 Peak [Ca 2+ ] i increased incrementally from 1 to 20 aP stimuli ( fig. 3C ). The degree of inhibition by dexmedetomidine was comparable across this range of stimuli (55 to 62% of control; n = 6; fig. 3D ), with 62 ± 3% of control at 20 aPs (95% CI, 0.48 to 0.78) comparable to the degree of inhibition of SV exocytosis. Similar results were observed for 0.5 μM clonidine (63 to 74% of control; n = 8; data not shown).
Correlation between aP-evoked SV exocytosis and Ca 2+ influx was measured over a range of aP stimuli to quantify PERIOPERATIVE MEDICINE the efficiency of exocytosis at different degrees of Ca 2+ influx (Ca 2+ -exocytosis coupling). The relationship between paired exocytosis-Ca 2+ influx data for dexmedetomidine overlapped control data ( fig. 4) , confirming that the effect of dexmedetomidine on SV exocytosis is directly proportional to reduction in Ca 2+ influx with no measurable effect on the Ca 2+ sensitivity of exocytosis.
While n-type, voltage-gated Ca 2+ channels (VGCCs) are closely coupled to depolarization-evoked release of norepinephrine in sympathetic neurons, 30, 31 SV exocytosis in nonadrenergic neurons involves contributions from both n-and P/Q-type VGCCs. [32] [33] [34] [35] We used VGCC subtypespecific peptide neurotoxins to evaluate the roles of n-and P/Q-type VGCCs in the inhibitory effects of dexmedetomidine on hippocampal SV exocytosis ( fig. 5 ). The specific n-type VGCC blocker ω-conotoxin GIVa inhibited exocytosis to 62 ± 9% of control (95% CI, 0.40 to 0.83) after 10 s of 10-Hz stimulation at 2 mM [Ca 2+ ] e . Treatment with dexmedetomidine further inhibited exocytosis to 47 ± 10% of control (95% CI, 0.22 to 0.72), consistent with an effect of dexmedetomidine on exocytosis mediated by P/Q-type channels (n = 7; fig. 5a ). The specific P/Qtype VGCC toxin ω-agatoxin IVa inhibited SV exocytosis to 53 ± 10% of control (95% CI, 0.29 to 0.78). Treatment with dexmedetomidine further inhibited exocytosis to 33 ± 7% of control (95% CI, 0.17 to 0.49), consistent with an effect of dexmedetomidine on exocytosis mediated by uninhibited n-type channels as well (n = 8; fig. 5B ). Thus, dexmedetomidine inhibits exocytosis mediated by the two major presynaptic VGCC subtypes known to be coupled to SV exocytosis in the hippocampus. [32] [33] [34] [35] Similar results were observed for 0.5 μM clonidine (data not shown).
Presynaptic Interaction between Dexmedetomidine and Isoflurane
Clinical features of α 2 -ar agonists include their ability to produce sedation and to increase the potency of general 5, 6 Since volatile anesthetics such as isoflurane also inhibit SV exocytosis in hippocampal neurons, 1, 13, 14 we studied the interaction between isoflurane and dexmedetomidine in suppressing exocytosis ( fig. 6 ). Isoflurane inhibited exocytosis in a concentrationdependent manner (n = 5, fig. 6a ): 2 minimum alveolar concentration isoflurane inhibited exocytosis to 63 ± 8% of control (95% CI, 0.45 to 0.82); addition of 0.1 μM dexmedetomidine further inhibited exocytosis to 42 ± 5% of control (95% CI, 0.31 to 0.53; n = 7; fig. 6B ), greater than the effect of dexmedetomidine alone (54 ± 5%, 95% CI, 0.42 to 0.65; fig. 1e ). The effect of isoflurane did not involve activation of α 2 -ars as it was not prevented by the subtype nonselective α 2 -ar antagonist atipamezole, which also had no effect on exocytosis alone (n = 7; fig. 6C ).
Discussion
noradrenergic signaling plays important roles in controlling the endogenous sleep-awake cycle and general anesthesia, 36 but the mechanisms involved in the interaction between general anesthetics and the anesthetic-sparing effects of α 2 -ar agonists are unclear. Potentiation of general anesthesia (anesthetic sparing) is a characteristic neuropharmacologic effect of α 2a -ar agonists. 5,6,37 a well-known action of α 2a -ar agonists is their modulation of norepinephrine release through presynaptic autoreceptors (receptors for the 
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same transmitter released by the neuron), but elegant genetic studies targeting cell-specific α 2 -ar receptor expression indicate that classical presynaptic noradrenergic neuron autoreceptor effects are not involved in this anesthetic-sparing action. 9, 10 Here, we show that the α 2 -ar agonists dexmedetomidine and clonidine inhibit SV exocytosis and Ca 2+ entry in nonadrenergic hippocampal neurons by a heteroreceptor (receptors for a transmitter not released by the neuron) α 2a -ar-mediated effect. Moreover, this mechanism is additive with inhibition of SV exocytosis by the volatile anesthetic isoflurane (for summary of possible mechanisms see fig. 7 ).
advances in fast microscopic imaging and sensitive fluorescent biosensors allowed us to determine the effects of α 2ar agonists on both aP-evoked SV exocytosis 22, 23, 27 and Ca 2+ influx 24 in intact central nervous system neurons without interference from noradrenergic innervation. We observed that the clinically used α 2 -ar agonists dexmedetomidine Fig. 3B ) with data for Ca 2+ influx (from Fig. 3D ) for 1 to 20 AP stimuli. Data are fitted to a linear model (exocytosis = 0.0107 ± 0.0014 intracellular Ca 2+ [{Ca 2+ } i ] to 0.00389 ± 0.00458). Presynaptic α 2 -Adrenoceptors Modulate Exocytosis and clonidine inhibited SV exocytosis from hippocampal neurons through activation of α 2a -ars to reduce Ca 2+ influx mediated by both n-type and P/Q-type VGCCs. Moreover, the highly selective α 2 -ar agonist dexmedetomidine potentiated the presynaptic effects of isoflurane to reduce SV exocytosis. This provides a putative presynaptic target for the anesthetic-sparing properties of α 2 -ar agonists, 6 a clinically relevant pharmacologic interaction that allows reduced dosing of general anesthetics to mitigate their dangerous sideeffect profiles. 37 Contrary to our findings, conventional electrophysiologic studies have not detected dexmedetomidine or medetomidine effects on basal neurotransmission of Schaffer collaterals in rat hippocampus. 38, 39 Field excitatory postsynaptic potentials (fePSPs) are the sum of individual signals from many cells, including inhibitory γ-aminobutyric acid-mediated (GaBaergic) interneurons that have extensive arbors that innervate pyramidal cells. Individual GaBaergic interneurons can powerfully inhibit thousands of excitatory pyramidal neurons. activity of postsynaptic neurons also contributes to fePSPs such that fePSPs are affected both by inhibitory signals from GaBaergic interneurons and by postsynaptic mechanisms, possibly explaining the insensitivity of the fePSP to the effects of dexmedetomidine. In contrast, the method we used selectively reports activity from presynaptic boutons of only a single cell, most commonly nonGaBaergic neurons as detected by vGaT immunoreactivity. 14 although we did not routinely determine neuronal phonotype at the time of this study, we did screen 29 of the 96 neurons described here using vGaT-Oyster labeling, and all 29 were negative (i.e., not GaBaergic and thus assumed to be glutamatergic; data not shown). Further studies of neurons of defined transmitter phenotype will be necessary to determine whether there are transmitter-specific differences in α 2a -ar modulation of SV exocytosis. . Data are expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, not significant by one-way repeated measures ANOVA followed by Tukey multiple comparison test.
We have shown previously that isoflurane inhibits SV exocytosis in hippocampal neurons. 13, 14 While the effects of dexmedetomidine and isoflurane on exocytosis are additive, their molecular mechanisms are distinct since the isoflurane effect is insensitive to α 2 -ar antagonism. The inhibitory effects of volatile anesthetics on hippocampal exocytosis are thus independent of α 2 -ar-coupled G protein signaling but rather appear to involve primarily direct depression of presynaptic, voltage-gated na + channels (na v ) to reduce presynaptic excitability. 13, 40 In contrast, the sedative and anesthetic-sparing properties of α 2 -ar agonists are mediated by G protein-coupled receptors, specifically through the Gα i2 isoform. 41 The relevant G protein-regulated downstream targets for the presynaptic effects of α2-ar agonists on Ca 2+ influx and in turn SV exocytosis remain to be established. Clonidine can inhibit both n-and P/Q-type Ca 2+ currents in mouse amygdala slices, consistent with our findings of effects on both pathways of Ca 2+ entry. 42 Moreover, a recent study shows that dexmedetomidine inhibits na v 1.8 currents in rat dorsal root ganglion neurons by increasing activation threshold and decreasing aP firing, suggesting that α 2a -ar agonists might also affect aP frequency and propagation. 43 These parallel pathways of inhibition result in additive effects of isoflurane and α 2 -ar agonists on both Ca 2+ influx and SV exocytosis, thus providing a plausible cellular mechanism for their pharmacodynamic anesthetic-sparing interactions in vivo. 9,10 electrophysiologic studies or optical measurements of aP waveforms using microbial rhodopsin-based biosensors 44 should further determine directly whether α 2a -ar agonists affect presynaptic aP properties.
The α 2 -ars were among the first presynaptic receptors identified by their role as autoreceptors coupled to inhibition of norepinephrine release. 29 Previous studies suggested that the sedative and anesthetic-sparing effects of selective α 2 -ar agonists involved reductions in noradrenergic neurotransmission through autoreceptor activation. 45 However, more recent studies have implicated effects of α 2 -ar agonists on nonadrenergic neurons in these actions. 9, 46, 47 Genetically engineered mice that express α 2a -ars only in noradrenergic terminals show minimal neurologic effects of the α 2 -ar agonist medetomidine, including loss of righting reflex and anesthetic sparing, in contrast to a strong hypnotic effect in wild-type littermates. 9 In another study in vivo, acute knockdown of α 2a -ar expression in the lC failed to affect dexmedetomidine-induced sedation. 46 These findings suggest that α 2a -ars on nonadrenergic neurons mediate their sedative effects. Furthermore, dopamine-βhydroxylase knockout mice that have no synaptic norepinephrine release show enhanced sensitivity to and delayed emergence from dexmedetomidine-induced hypnosis compared to wild-type mice. 47 This further supports the concept that norepinephrine release from lC neurons is not critical Fig. 7 . Presynaptic mechanisms relevant to the effects of α 2 -adrenergic receptor (AR) agonists on synaptic vesicle exocytosis. Inhibition by the volatile anesthetic isoflurane (ISO) is due primarily to inhibition of voltage-gated Na + channels (Na v ) rather than direct inhibition of voltage-gated Ca 2+ channels (Ca v ) or soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins. Effects of α 2A -AR agonists such as dexmedetomidine (DEX) and clonidine (CLO) are mediated by G-protein-coupled receptors, specifically through the Gα i2 isoform. The relevant downstream targets of G-protein activation by α 2A -AR are unknown; plausible candidates include activation of K + channels, inhibition of Ca v , and/or by reduced action potential (AP)-induced depolarization through inhibition of Na v . Use of the fluorescent biosensor synaptophysin-pHluorin (syn-pH; green circles) to measure exocytosis is also shown; increased fluorescence is induced by the increase in pH after synaptic vesicle fusion (right).
Presynaptic α 2 -Adrenoceptors Modulate Exocytosis for dexmedetomidine-induced hypnosis but rather supports a role for direct α 2 -ar agonist actions on nonadrenergic neurons in their sedative and anesthetic-sparing actions. Our findings demonstrate a presynaptic site of interaction between the volatile anesthetic isoflurane and the highly selective α 2 -ar agonist dexmedetomidine in reducing SV exocytosis by blocking Ca 2+ influx in hippocampal neuron axon terminals, a mechanism previously implicated in the presynaptic anesthetic actions of volatile anesthetics. 13, 14 The role of presynaptic α 2 -ar agonist-mediated inhibition of neurotransmitter release from nonadrenergic neurons in specific anesthetic endpoints is compelling, but identification of the relevant neuronal networks involved will require further study. The hypnotic effects of α 2 -ar agonists were initially proposed to be mediated by presynaptic α 2a -ars on noradrenergic projections from the lC to mimic endogenous sleep mechanisms. 45, 48 While indirect neurophysiologic studies in vivo continue to invoke this mechanism, 49 genetic studies provide strong evidence that nonadrenergic, not noradrenergic, α 2a -ars mediate the sedative, hypnotic, and anesthetic-sparing actions of α 2 -ar agonists. 9, 10, 46, 47 Plausible targets for the hypnotic and anesthetic-sparing effects of α 2 -ar agonists include direct suppression of synaptic transmission in corticocortical 3 and thalamocortical networks. 48, 49 a recent study in vivo using the TetTag-hM 3 D q system to record and reactivate neuronal groups activated by dexmedetomidine implicates the preoptic hypothalamus and neighboring dorsal structures in dexmedetomidineinduced sedation. 46 although our studies were conducted in hippocampal neurons and are therefore most directly relevant to the amnestic properties of the α 2 -ar agonist dexmedetomidine, 50, 51 the effects observed involve fundamental mechanisms regulating SV exocytosis in all neurons. 52 Given the widespread expression of α 2a -ar receptors, 17, 18 this pharmacodynamic interaction is likely to apply throughout the central nervous system. Identification of the locations of the specific nonadrenergic α 2a -ars involved in the multiple neuropharmacologic endpoints essential for enhancing general anesthetic effects is critical to the development of more targeted agents with improved specificity and therefore safety. Modulation of synaptic transmission by α 2a -ars might also contribute to their emerging organoprotective effects, further augmenting their clinical utility by both reducing anesthetic doses and preserving organ function. 53 
